In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients

Single photon emission computed tomography (SPECT) using (123)I iodobenzamide (IBZM) as tracer substance has been shown to be a useful tool to visualize dopamine 2 (D2) receptor occupancy. We investigated the striatal D2 receptor occupancy of zotepine which is referred to the class of atypical antip...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacology 2001-09, Vol.157 (3), p.236
Main Authors: Barnas, C, Quiner, S, Tauscher, J, Hilger, E, Willeit, M, Küfferle, B, Asenbaum, S, Brücke, T, Rao, M L, Kasper, S
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - adverse effects
Antipsychotic Agents - blood
Antipsychotic Agents - pharmacokinetics
Dibenzothiepins - adverse effects
Dibenzothiepins - blood
Dibenzothiepins - pharmacokinetics
Female
Humans
Iodobenzenes
Male
Neostriatum - diagnostic imaging
Neostriatum - metabolism
Radiopharmaceuticals
Receptors, Dopamine D2 - drug effects
Schizophrenia - diagnostic imaging
Schizophrenia - metabolism
Tomography, Emission-Computed, Single-Photon
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Single photon emission computed tomography (SPECT) using (123)I iodobenzamide (IBZM) as tracer substance has been shown to be a useful tool to visualize dopamine 2 (D2) receptor occupancy. We investigated the striatal D2 receptor occupancy of zotepine which is referred to the class of atypical antipsychotic drugs. (123)I IBZM and SPECT were used to visualize striatal dopamine 2 (D2) receptor occupancy in zotepine-treated schizophrenic patients. Two groups of schizophrenic patients receiving either 150 mg/day zotepine (n=6) or 300 mg/day (n=6) underwent examination. For the quantification of striatal D2 receptor occupancy, striatal IBZM binding in patients treated with antipsychotics was compared to untreated healthy controls (n=8) reported earlier. Zotepine led to a mean overall striatal D2 receptor occupancy of 73%. Patients with 150 mg daily showed a significantly lower occupancy (65.8%, SD=6.2) than patients with 300 mg/day (77.8%, SD=10.7; P
ISSN:0033-3158
DOI:10.1007/s002130100813